| Literature DB >> 26642052 |
Shaowei Jiang1, Aihua Fei1, Ya Peng2, Jun Zhang3, You-Ran Lu3, Hai-Rong Wang1, Miao Chen1, Shuming Pan1.
Abstract
BACKGROUND: Endovascular mechanical thrombectomy is emerging as a promising therapeutic approach for acute ischemic stroke and show some advantages. However, the data of predicting clinical outcome after thrombectomy with Solitaire retriever were limited. We attempt to identify prognostic factors of clinical outcome in patients with acute ischemic stroke undergoing thrombectomy with Solitaire retriever.Entities:
Mesh:
Year: 2015 PMID: 26642052 PMCID: PMC4671621 DOI: 10.1371/journal.pone.0144452
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Basline of clinical and neuroimaging characteristics of population.
| Demographics | Value(n, % Unless Otherwise Specified) |
|---|---|
| Age (years), mean ± SD | 63.12±13.98(21–85) |
| Sex (male: female)—no.(%) | (55:34)(61.80%:38.20%) |
| NIHSS score on admission, mean ± SD | 19.17±4.64(10–34) |
| NIHSS score on admission, median | 19 |
| NIHSS score at discharge | 10.52±11.09(0–42) |
| Cerebrovascular risk factors | |
| Atrial fibrillation | 44(49.44%) |
| Coronary artery disease or myocardial infarction | |
| Diabetes mellitus | 13(14.61%) |
| Serum glucose, mmol/l mean±(SD) (range) | 7.97±3.57(3.9–20) |
| Hypertension | 26 (47.3%) |
| Blood Pressure, mmHg mean±(SD) (range) | |
| Systolic | 136.48±24.34 (87–192) |
| Diastolic | 80.39±13.86 (52–112) |
| TG>2.02mmol/l—no.(%) | 5(9.1) |
| Triacylglycerol, mmol/l mean±(SD) (range) | 1.79±0.98 (0.68–4.71) |
| TC>5.7mmol/l—no.(%) | 13(23.6) |
| Cholesterol, mmol/l mean±(SD) (range) | 4.40±0.89 (2.19–6.89) |
| Stroke cause on day 7—no. (%) | |
| Cardiogenic embolism | 42(47.19%) |
| Large-artery atherosclerosis | 39(43.82%) |
| Other | 5(5.62%) |
| Undetermined | 3(3.37%) |
| Distribution of vascular occlusion, stenosis and dissection | |
| Anterior circulation | 81(91.01%) |
| MCA M1/M2 | 62(69.67%) |
| ACA A1/A2 | 2(2.25%) |
| ICA | 4(4.49%) |
| Tandem occlusion (ICA1 MCA M1/M2) | 13(14.61%) |
| Posterior circulation | 7(7.87%) |
| Basilar | 4(4.49%) |
| vertebral | 1(1.12%) |
| Tandem occlusion(vertebral+ Basilar, Basilar+ PCA P1/P2) | 2(2.25%) |
| Anterior and posterior circulation | 1(1.12%) |
| Site of Stenosis | 17(19.10) |
| MCA—no.(%) | 13(14.61) |
| ICA—no.(%) | 2(2.25) |
| BA—no.(%) | 2(2.25) |
| Site of Dissection | 5(5.62) |
| ICA—no.(%) | 4(4.49) |
| VA—no.(%) | 1(1.12) |
Data of mechanical thrombectomy with Solitaire.
| Demographics | Value(n, % Unless Otherwise Specified) |
|---|---|
| Onset to needle,min mean±(SD)(range) | 170.64 ±67.73(60–356) |
| Door to needle,min mean±(SD)(range) | 69.2±32.44(30–180) |
| Needle to recanalization,min mean±(SD)(range) | 114.51±63.65(49–420) |
| Onset to recanalization,min mean±(SD)(range) | 285.15±94.23(120–660) |
| Number of passes with Solitaire FR mean±(SD)(range) | 2.19±1.20(1–6) |
| 1 | 33(37.08%) |
| 2 | 21(23.60%) |
| 3 | 23(25.84%) |
| >3 | 12(13.48%) |
| Multimodal endovascular therapy | |
| Solitaire FR only | 32(35.96%) |
| IA urokinase—no.(%) | 25(28.09%) |
| Dose of urokinase 10,000 IU mean±(SD)(range) | 274194±123741(100000–550000) |
| Balloon—no.(%) | 27(30.3%) |
| Stent-assisted angioplasty—no.(%) | 28(31.46%) |
| Decompressive craniectomy—no.(%) | 12(13.48%) |
| Aspiration thrombectomy with Penumbra | 2(2.24%) |
Outcome after endovascular thrombectomy treatment.
| Demographics | Value(n, % Unless Otherwise Specified) |
|---|---|
| TICI recanalization | |
| 0 | 6(6.74%) |
| 1 | 5(5.62%) |
| 2a | 18(20.22%) |
| 2b | 25(28.09%) |
| 3 | 35(39.33%) |
| Success of recanalization—no.(%) | 78(87.64) |
| Complete recanalization (TICI 3)—no.(%) | 35(39.33) |
| Partial recanalization (TICI 2a/2b)—no.(%) | 43(48.31) |
| Recanalization failure (TICI 0/1)—no.(%) | 11(12.36) |
| Improvement of clinical symptom—no.(%)(NIHSS ≥4) | 68(51.96) |
| Complete recovery (NIHSS = 0)—no.(%) | 14(15.73) |
| mRS ≤ 2 at 90 days—no.(%) | 37 (41.57) |
| Infarction Haemorrhagic Transformation—no.(%) | 42(47.2%) |
| Asymptomatic HI-1—no.(%) | 10(11.24%) |
| HI-2—no.(%) | 13(14.61%) |
| PH-1—no.(%) | 4(4.49%) |
| PH-2—no.(%) | 4(4.49%) |
| Symptomatic PH-2—no.(%) | 7(7.87%) |
| IVH—no.(%) | 4(4.49%) |
Comparison between patients who had favorable and unfavorable outcome at 3 months.
| Factors | MRS≤2 | MRS≥3 | Univariate analysis OR(95%CI) | Multivariate analysis OR(95%CI) |
|---|---|---|---|---|
| Sex | ||||
| Male | 29(78.38) | 24(46.15) | 1.00 | 1.00 |
| Female | 8(21.62) | 28(53.85) | 4.23(1.63,10.98) | 2.89(0.92,9.11) |
| NIHSS score on admission | ||||
| <20 | 29(78.38) | 22(42.31) | 1.00 | 1.00 |
| ≥20 | 8(21.62) | 30(57.69) | 4.94(1.90,12.87) | 5.25(1.66,16.63) |
| NIHSS 7,mean±SD | 2.49±2.57 | 16.23±11.29 | 1.82(1.38,2.39) | – |
| Diabete | ||||
| No | 36(97.30) | 40(76.92) | 1.00 | – |
| Yes | 1(2.70) | 12(23.08) | 10.80(1.34,87.23) | – |
| Serum glucose,mean±SD | 6.53±2.38 | 9.43±4.41 | 1.37(1.13,1.66) | 1.31(1.06,1.63) |
| Systolic,mean±SD | 137.19±22.96 | 149.62±29.19 | 1.02(1.00,1.03) | - |
| Diastolic,mean±SD | 80.19±12.28 | 86.13±14.20 | 1.03(1.00,1.07) | - |
| Atrial fibrillation | ||||
| No | 24(64.86) | 21(40.38) | 1.00 | – |
| Yes | 13(35.14) | 31(59.62) | 2.72(1.14,6.52) | – |
| Needle to recanalizatio,mean±SD | 96.70±47.72 | 127.17±70.63 | 1.01(1.00,1.02) | 2.97(1.00,8.83) |
| Onset to recanalization | ||||
| <5H | 24(64.86) | 23(44.23) | 1.00 | – |
| ≥5H | 13(35.14) | 29(55.77) | 2.33(0.98,5.55) | – |
Analysis of potential factors predicting symptomatic intracranial hemorrhage (sICH) at day 1.
| Factors | No sICH | sICH | Univariate analysis OR(95%CI) | Multivariate analysis OR(95%CI) |
|---|---|---|---|---|
| Sex | ||||
| Male | 51(65.38) | 2(18.18) | 1 | 1 |
| Female | 27(34.62) | 9(81.82) | 8.50(1.71,42.17) | 10.34(1.34,79.59) |
| NIHSS score on admission | ||||
| <20 | 49(62.82) | 2(18.18) | 1 | 1 |
| ≥20 | 29(37.18) | 9(81.82) | 7.60(1.54,37.64) | 9.73(1.34,70.69) |
| NIHSS 7,mean±SD | 8.92±10.57 | 21.82±7.87 | 1.09(1.03,1.15) | – |
| Diabete | ||||
| No | 70(89.74) | 6(54.55) | 1 | 1 |
| Yes | 8(10.26) | 5(45.45) | 7.29(1.81,29.40) | 7.34(1.32,40.84) |
| Serum glucose,mean±SD | 7.66±3.62 | 12.32±4.10 | 1.25(1.07,1.47) | – |
| Needle to recanalization,mean±SD | 110.92±54.16 | 139.91±110.66 | 1.01(1.00,1.01) | 1.01(1.00,1.02) |
| Onset to recanalization | ||||
| <5H | 41(52.56) | 6(54.55) | 1 | – |
| ≥5H | 37(47.44) | 5(45.45) | 0.92(0.26,3.28) | – |
Analysis of potential factors predictive of mortality at 3 months.
| Factors | Death | Alive | Univariate analysis OR(95%CI) | Multivariate analysis OR(95%CI) |
|---|---|---|---|---|
| Age | ||||
| ≤60 | 4(19.05) | 30(44.12) | 1 | – |
| 60–70 | 6(28.57) | 15(22.06) | 3.00(0.73,12.27) | – |
| >70 | 11(52.38) | 23(33.82) | 3.59(1.01,12.73) | – |
| NIHSS score on admission | ||||
| <20 | 4(19.05) | 47(69.12) | 1 | 1 |
| ≥20 | 17(80.95) | 21(30.88) | 9.51(2.85,31.73) | 9.38(2.41,36.50) |
| NIHSS 7,mean±SD | 25.81±11.09 | 5.79±5.38 | 1.30(1.16,1.44) | – |
| Serum glucose,mean±SD | 10.26±4.33 | 7.58±3.63 | 1.17(1.03,1.33) | – |
| Affected hemisphere on baseline imaging | ||||
| Left_hemisphere | 8(38.10) | 31(45.59) | 1 | – |
| Right_hemisphere | 7(33.33) | 32(47.06) | 0.85(0.27,2.62) | – |
| Multiple | 6(28.57) | 5(7.35) | 4.65(1.13,19.21) | – |
| Number of passes with Solitaire FR | ||||
| 1 | 4(19.05) | 29(42.65) | 1 | – |
| 2 | 8(38.10) | 13(19.12) | 4.46(1.14,17.50) | – |
| 3 | 6(28.57) | 17(25.00) | 2.56(0.63,10.37) | – |
| >3 | 3(14.29) | 9(13.24) | 2.42(0.45,12.88) | – |
| Needle to recanalization,mean±SD | 152.1±80.1 | 102.9±53.2 | 1.01(1.00,1.02) | – |
| Onset to recanalization | ||||
| <5H | 7(33.33) | 40(58.82) | 1 | 1 |
| ≥5H | 14(66.67) | 28(41.18) | 2.86(1.02,7.99) | 5.23(1.34,20.41) |
| Infarction Haemorrhagic Transformation | ||||
| NO_sICH | 13(61.90) | 65(95.59) | 1 | 1 |
| sICH | 8(38.10) | 3(4.41) | 13.33(3.11,57.09) | 10.19(1.80,57.83) |
Factors distributed between female and male.
| Male | Female | Test |
| |
|---|---|---|---|---|
| Age (mean±SD) | 59.5 ± 14.5 | 68.4 ± 11.5 |
| 0.003 |
| NIHSS score on admission(mean±SD) | 18.4 ± 5.5 | 19.8 ± 4.5 |
| 0.223 |
| IA urokinase | ||||
| Yes | 20 | 11 | Chi-2 | 0.485 |
| No | 33 | 25 | ||
| Dose of urokinase (x 1,000 IU) mean±(SD) | 10.47 ± 15.91 | 8.19 ± 13.64 |
| 0.485 |
| Diabetes | ||||
| Yes | 5 | 8 | Chi-2 | 0.094 |
| No | 48 | 28 | ||
| Serum glucose(mean±SD) | 7.80 ± 4.19 | 8.82 ±3.48 |
| 0.240 |
| Hypertension | ||||
| Yes | 31 | 20 | Chi-2 | 0.784 |
| No | 22 | 16 | ||
| Atrial fibrillation | ||||
| Yes | 20 | 24 | Chi-2 | 0.007 |
| No | 33 | 12 | ||
| Onset to needle (mean±SD) | 175.5 ± 64.0 | 170.0 ± 86.2 |
| 0.735 |
| Needle to recanalization (mean±SD) | 117.0 ± 71.9 | 110.2 ± 51.2 |
| 0.633 |
| Onset to recananlization (mean±SD) | 290.9 ± 101.8 | 280.2 ± 88.3 |
| 0.617 |
** indicated significant difference.